Targeting CD40

References

• Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi J P, van Kooten C, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881–922
   PubMed Web of Science ®Google Scholar
• Szocinski J L, Khaled A R, Hixon J, Halverson D, Funakoshi S, Fanslow W C, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 2002; 100: 217–223
   PubMed Web of Science ®Google Scholar
• Hollenbaugh D, Grosmaire L S, Kullas C D, Chalupny N J, Braesch-Andersen S, Noelle R J, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. Embo J 1992; 11: 4313–4321
   PubMed Web of Science ®Google Scholar
• Graf D, Korthauer U, Mages H W, Senger G, Kroczek R A. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 1992; 22: 3191–3194
   PubMed Web of Science ®Google Scholar
• Peitsch M C, Jongeneel C V. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol 1993; 5: 233–238
   PubMed Web of Science ®Google Scholar
• Arch R H, Gedrich R W, Thompson C B. Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death. Genes Dev 1998; 12: 2821–2830
   PubMed Web of Science ®Google Scholar
• Chung J Y, Park Y C, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115: 679–688
   PubMed Web of Science ®Google Scholar
• Fluckiger A C, Rossi J F, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80: 3173–3181
   PubMed Web of Science ®Google Scholar
• Crawford D H, Catovsky D. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 1993; 80: 40–44
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans H C, Beverstock G C, Mollevanger P, Wessels H W, Hoogendoorn E, Willemze R, et al. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. Blood 1994; 84: 3134–3141
   PubMed Web of Science ®Google Scholar
• Johnson P W, Watt S M, Betts D R, Davies D, Jordan S, Norton A J, et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 1993; 82: 1848–1857
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780–789
   PubMed Web of Science ®Google Scholar
• Liu Y J, Mason D Y, Johnson G D, Abbot S, Gregory C D, Hardie D L, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 1991; 21: 1905–1910
   PubMed Web of Science ®Google Scholar
• Funakoshi S, Longo D L, Beckwith M, Conley D K, Tsarfaty G, Tsarfaty I, Armitage R J, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787–2794
   PubMed Web of Science ®Google Scholar
• Schattner E J, Mascarenhas J, Bishop J, Yoo D H, Chadburn A, Crow M K, et al. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood 1996; 88: 1375–1382
   PubMed Web of Science ®Google Scholar
• Young L S, Eliopoulos A G, Gallagher N J, Dawson C W. CD40 and epithelial cells: across the great divide. Immunol Today 1998; 19: 502–506
   PubMedGoogle Scholar
• Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1996; 56: 1909–1916
   PubMed Web of Science ®Google Scholar
• Westendorf J J, Ahmann G J, Armitage R J, Spriggs M K, Lust J A, Greipp P R, et al. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 1994; 152: 117–128
   PubMed Web of Science ®Google Scholar
• Francisco J A, Siegall C B. Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies. Leuk Lymphoma 1998; 30: 237–245
   PubMed Web of Science ®Google Scholar
• Geldart T, Illidge T. Anti-CD 40 monoclonal antibody. Leuk Lymphoma 2005; 46: 1105–1113
   PubMed Web of Science ®Google Scholar
• Farahani M, Treweeke A T, Toh C H, Till K J, Harris R J, Cawley J C, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005; 19: 524–530
   PubMed Web of Science ®Google Scholar
• Vonderheide R H, Dutcher J P, Anderson J E, Eckhardt S G, Stephans K F, Razvillas B, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001; 19: 3280–3287
   PubMed Web of Science ®Google Scholar
• Wierda W G, Cantwell M J, Woods S J, Rassenti L Z, Prussak C E, Kipps T J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917–2924
   PubMed Web of Science ®Google Scholar
• Takahashi S, Yotnda P, Rousseau R F, Mei Z, Smith S, Rill D, et al. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001; 8: 378–387
   PubMed Web of Science ®Google Scholar
• Messmer D, Kipps T J. CD154 gene therapy for human B-cell malignancies. Ann NY Acad Sci 2005; 1062: 51–60
   PubMed Web of Science ®Google Scholar
• Bonsignori M, D'Costa S, Surman S, Hurwitz J L. A combination of 5-fluorouracil and membrane-bound antibody inhibits B-cell lymphoma growth in a mouse model system. Leuk Lymphoma 2007; 48: 406–409
   PubMed Web of Science ®Google Scholar
• Law C L, Gordon K A, Collier J, Klussman K, McEarchern J A, Cerveny C G, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331–8338
   PubMed Web of Science ®Google Scholar
• Tai Y T, Catley L P, Mitsiades C S, Burger R, Podar K, Shringpaure R, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004; 64: 2846–2852
   PubMed Web of Science ®Google Scholar
• Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006; 91: 104–112
   PubMed Web of Science ®Google Scholar
• Konecny G E, Pegram M D. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology (Huntingt) 2004; 18: 32–36
   PubMedGoogle Scholar